Invivyd(IVVD)
NEW HAVEN, CTBiotechnology
Focus: Invivyd is a publicly traded biotechnology company focused on developing therapeutic antibodies for infectious diseases, particularly COVID-19 variants. The company operates with a lean commercial footprint and significant R&D investment focused on advancing monoclonal antibody programs.
Profile data last refreshed 11h ago · AI intelligence enriched 1mo ago
Funding Stage
PUBLIC
Open Jobs
13+1 this month
Stable — net +1 jobs in 30d
4 added, 3 removed. Backfill posture.
Should You Work at Invivyd?
AI assessmentHigh-risk, high-reward opportunity best suited for antibody specialists willing to accept significant cash/execution risk for potential pipeline upside; not recommended for those seeking stability.
Why Work Here
- Early-stage pipeline with multiple Phase 3 programs (5 active trials) targeting high-prevalence infectious disease market with commercial momentum building
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Mid-stage
2 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$25M
Pipeline & Clinical Trials
VYD222
COVID-19Clinical Trials (1)
NCT06004128Provide Pre-approval Single-patient Expanded Access (Compassionate Use) of VYD222 for Patients With Symptomatic COVID-19 Refractory to Other Treatments
N/AHelp build intelligence for Invivyd
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.